| Literature DB >> 25089876 |
Chieh-Hung Huang1, Yu-Yi Chan2, Ping-Chung Kuo3, Yu-Fon Chen4, Ren-Jie Chang5, Ih-Sheng Chen6, Shwu-Jen Wu7, Tian-Shung Wu8.
Abstract
Phytochemical investigation of the roots and stems of Illigera luzonensis afforded two new aporphine alkaloids (1) and (2), one new bisdehydroaporphine alkaloid (3), and one new benzenoid (4), along with 28 known structures. The structures of new compounds were elucidated by spectral and MS analysis. Among the isolated compounds, (1) and (4-13) were subjected into the examination for their inhibitory effects on the aggregation of washed rabbit platelets.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25089876 PMCID: PMC4159803 DOI: 10.3390/ijms150813424
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
1H and 13C NMR data of compounds 1 and 2 a.
| Position | 1 | 2 | |
|---|---|---|---|
| dH (J, Hz) | |||
| 1 | 142.2 | ||
| 1a | 116.7 | ||
| 1b | 125.2 | ||
| 2 | 147.4 | ||
| 3 | 6.53, s | 107.0 | 6.52, s |
| 3a | 123.2 | ||
| 4 | 3.10, m | 28.1 | 2.91, m |
| 2.74, dt (16.2, 3.8) | 2.68, br d (15.6) | ||
| 5 | 3.43, td (12.6, 3.8) | 47.2 | 3.12, m |
| 3.67, m | 3.00, dd (11.2, 5.2) | ||
| 6a | 4.25, dd (14.0, 4.8) | 54.9 | 3.62, br d (13.8) |
| 7 | 2.9, t (14.0) | 33.7 | |
| 3.12, dd (14.0, 4.8) | 2.90, br d (13.8) | ||
| 7a | 127.0 | 2.59, t (13.8) | |
| 8 | 6.85, s | 114.5 | 6.82, s |
| 9 | 145.5 | ||
| 10 | 145.7 | ||
| 11 | 7.63, s | 110.0 | 7.63, s |
| 11a | 122.5 | ||
| OH-9 b | 5.71, br s | 5.71, br s | |
| OCH3-10 | 3.99, s | 56.2 | 4.04, s |
| –OCH2O– | 5.96, d (0.8) | 100.9 | 5.94, d (1.8) |
| 6.11, d (0.8) | 6.09, d (1.8) | ||
| –CH2CN | 4.09, d (17.6) | ||
| 3.73, d (17.6) | |||
| CN | 110.2 | ||
a 1H NMR data were measured at 400 MHz for 1, and 200 MHz for 2. 13C NMR data were measured at 100 MHz for 1. The assignments are based on 1H–1H COSY, NOESY, HMQC and HMBC spectra; b D2O exchangeable.
Figure 1Selected HMBC (→) and NOESY (↔) spectrum for compounds 1–4.
Antiplatelet aggregation effects of 1, 4, and 5–7.
| Aggregation (%) | ||||||
|---|---|---|---|---|---|---|
| Inducer | Control | Conc. (μg/mL) | 1 | 5 | 6 | 7 |
| AA (100 μM) | 90.2 ± 0.8 | 100 | 0.0 ± 0.0 **** | 0.0 ± 0.0 **** | 0.0 ± 0.0 **** | 0.0 ± 0.0 **** |
| 50 | 4.7 ± 2.8 **** | – | 5.8 ± 5.2 **** | 0.0 ± 0.0 **** | ||
| 20 | 48.0 ± 13.7 *** | – | 24.9 ± 14.1 **** | 16.5 ± 11.1 **** | ||
| 10 | 78.7 ± 4.2 *** | – | 68.4 ± 8.6 *** | 49.9 ± 14.2 *** | ||
| 5 | 85.6 ± 3.2 * | – | 86.9 ± 1.2 *** | 83.8 ± 2.0 *** | ||
| 2 | – | 0.0 ± 0.0 **** | – | – | ||
| 1 | – | 17.8 ± 11.4 **** | – | – | ||
| 0.5 | – | 30.6 ± 13.5 **** | – | – | ||
| 0.2 | – | 83.6 ± 2.5 *** | – | – | ||
| Thr (0.1 U/mL) | 94.5 ± 1.0 | 100 | 90.9 ± 2.1 * | 89.5 ± 3.2 * | 92.4 ± 2.1 | 80.3 ± 2.6 *** |
| 50 | – | – | – | – | ||
| 20 | – | – | – | – | ||
| Col (10 μM) | 85.6 ± 0.8 | 100 | 6.8 ± 2.1 **** | 0.0 ± 0.0 **** | 9.5 ± 1.0 **** | 9.5 ± 1.0 **** |
| 50 | – | – | – | – | ||
| 20 | – | – | – | – | ||
| PAF (2 ng/mL) | 84.9 ± 0.6 | 100 | 57.5 ± 5.1 **** | 0.0 ± 0.0 **** | 64.3 ± 3.1 **** | 0.0 ± 0.0 **** |
| 50 | – | 51.5 ± 0.7 **** | – | 54.1 ± 2.9 **** | ||
| 20 | – | 71.2 ± 2.1 **** | – | 76.4 ± 3.3 ** | ||
| 10 | – | 78.1 ± 3.0 ** | – | 81.5 ± 1.9 * | ||
| 5 | – | 81.6 ± 2.4 * | – | 84.3 ± 0.4 | ||
Values are means ± SD (n = 3–5); *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001, indicates statistical significance compared to control groups. Abbreviations: AA, arachidonic acid; Thr, thrombin; Col, collagen; PAF, platelet activating factor.
Antiplatelet aggregation effects of 8, and 11-13.
| Aggregation (%) | ||||||
|---|---|---|---|---|---|---|
| Inducer | Control | Conc. (μg/mL) | 8 | 11 | 12 | 13 |
| AA (100 μM) | 90.2 ± 0.8 | 100 | 0.0 ± 0.0 **** | – | 0.0 ± 0.0 **** | 0.0 ± 0.0 **** |
| 50 | – | 25.7 ± 12.4 **** | 0.0 ± 0.0 **** | – | ||
| 20 | – | 43.4 ± 17.2 *** | 11.9 ± 10.6 **** | – | ||
| 10 | – | 62.6 ± 15.2 ** | 54.3 ± 14.4 *** | – | ||
| 5 | 0.0 ± 0.0 **** | 70.5 ± 14.1 * | 85.1 ± 3.9 * | 0.0 ± 0.0 **** | ||
| 2 | 4.8 ± 2.6 **** | 88.0 ± 2.4 | 90.2 ± 0.8 | 43.0 ± 12.3 **** | ||
| 1 | 30.2 ± 13.5 **** | – | – | 77.3 ± 8.6 * | ||
| 0.5 | 43.8 ± 16.4 *** | – | – | – | ||
| 0.2 | 84.1 ± 2.4 *** | – | – | – | ||
| Thr (0.1 U/mL) | 94.5 ± 1.0 | 100 | 86.6 ± 0.8 **** | – | 12.5 ± 7.7 **** | 87.8 ± 2.1 ** |
| 50 | – | 90.5 ± 0.8 ** | – | – | ||
| 20 | – | – | – | – | ||
| Col (10 μM) | 85.6 ± 0.8 | 100 | 0.0 ± 0.0 **** | – | 7.1 ± 5.8 **** | 5.6 ± 1.1 **** |
| 50 | – | 71.3 ± 4.6 ** | – | – | ||
| 20 | – | – | – | – | ||
| PAF (2 ng/mL) | 84.9 ± 0.6 | 100 | 56.3 ± 6.4 *** | – | 0.0 ± 0.0 **** | 71.3 ± 1.1 **** |
| 50 | – | 67.0 ± 1.8 **** | 0.0 ± 0.0 **** | – | ||
| 20 | – | – | 58.2 ± 2.2 **** | – | ||
| 10 | – | – | 76.7 ± 1.2 **** | – | ||
| 5 | – | – | 82.2 ± 1.9 * | – | ||
Values are means ± SD (n = 3–5); *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001, indicates statistical significance compared to control groups.